On Dec. 29, 2025, a federal judge in Maine temporarily blocked the Department of Health and Human Services from implementing the 340B rebate pilot.

The Trump administration agreed to drop a controversial pilot that would have allowed drugmakers to give post-sales rebates ...

Data sovereignty key navigating 340B's future helps healthcare leaders build integrated data systems for compliance and ...

Many Americans may be unaware that the services they rely on every day through their local hospital are supported by a program called the 340B Drug Pricing Program.

This contributor column discusses a recent study that shows the 340B Program’s explosive growth is overwhelmingly due to utilization increases, not price. Payers have struggled with the increasing ...

The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all ...

On July 31, 2025, the Health Resources and Services Administration (HRSA), Office of Pharmacy Affairs (OPA) issued a 340B Drug Pricing Program notice (the “Notice”) announcing the launch of a ...

An obscure, supposedly free federal program is blowing a hole in state budgets – by depriving state governments of billions in corporate tax revenue and inflating costs for their public employee ...

On July 31, 2025, the Health Resources and Services Administration (“HRSA”) announced the availability of a voluntary 340B Rebate Model Pilot Program (the “340B Rebate Pilot” or the “Pilot”) that ...

The 340B Drug Pricing Program allows certain medical facilities to buy drugs at a discount to support care for low-income patients. Rhode Island's new law, Chapter 288, prevents drug makers from ...

More than three decades ago, Congress created the 340B program to help safety-net hospitals and clinics expand resources and care for underserved communities. By requiring pharmaceutical companies to ...